AstraZeneca (AZN) said Monday that a final overall survival analysis of its phase 3 study for patients with 1st line locally advanced or metastatic epidermal growth factor receptor-mutated, or EGFRm, non-small cell lung cancer showed improvement in key secondary endpoints.
The FLAURA2 phase 3 study evaluated Tagrisso in combination with pemetrexed and platinum-based chemotherapy in patients with EGFRm lung cancer.
"Tagrisso plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer," the company said.
The latest analysis is in line with the interim overall survival report and builds on the previously presented primary endpoint data, which demonstrated the longest-reported median progression-free survival in this setting, AstraZeneca said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.